Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 13, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (ANNX)
- Breaking News: MoBot’s Latest Update as of 07/02/25 11:00 AM
- Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
- Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
- 24/7 Market News Snapshot 12 May, 2025 – Annexon, Inc. Common Stock (NASDAQ:ANNX)
- Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones